1 138

Cited 10 times in

Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases

 Sung Yong Oh  ;  Won Seog Kim  ;  Seok Jin Kim  ;  Jin Seok Kim  ;  Sung-Hyun Kim  ;  Dae Ho Lee  ;  Jong-Ho Won  ;  In Gyu Hwang  ;  Min Kyoung Kim  ;  Soon Il Lee  ;  Jong Gwang Kim  ;  Deok-Hwan Yang  ;  Hye Jin Kang  ;  Chul Won Choi  ;  Jinny Park  ;  Young Jin Choi  ;  Hyo Jung Kim  ;  Jung Hye Kwon  ;  Cheolwon Suh  ;  Hyo-Jin Kim 
 AMERICAN JOURNAL OF HEMATOLOGY, Vol.84(12) : 826-829, 2009 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Combined Modality Therapy ; Disease Progression ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Humans ; Lymphoma, B-Cell, Marginal Zone/epidemiology* ; Lymphoma, B-Cell, Marginal Zone/pathology ; Lymphoma, B-Cell, Marginal Zone/therapy ; Male ; Middle Aged ; Orbital Neoplasms/epidemiology ; Orbital Neoplasms/pathology ; Orbital Neoplasms/therapy ; Prognosis ; Recurrence ; Republic of Korea/epidemiology ; Retrospective Studies ; Salvage Therapy ; Treatment Outcome ; Young Adult
Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses. In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23-82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1%) or PR (18.9%). In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse. Among those patients with advanced stage at relapse, 44 patients were treated. The overall response rate was 54.5% (24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95% CI: 11.3-56.9 months) and the estimated 5-year overall survival (OS) was 84.3%. The majority of them was controlled well with salvage treatment, and could achieve prolonged survival. However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS. Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.